The Surprising Surge in One-Time Titans and the Weight-Loss Drugmaker at All-Time Highs 3/29/23
CNBC's "Fast Money"
00:00
The Competitive Landscape for Lilly
Lilly to me kind of the front runner, just because of the broader base of their entire pipeline and the EPS growth that they're getting. That seems to be very hot and heavy right now. And in the meantime, these obesity drugs are getting bigger and bigger as a percentage of revenue. So they probably are in a position where they can likely win either way.
Play episode from 29:49
Transcript
